This study revealed the antiobesity effects of this compound through the activation of the TGR5 and FXR signaling pathways and its capacity to mitigate obesity and lipid metabolism issues by enhancing intestinal barrier dysfunction and reducing intestinal inflammation. Here, GPBAR1 is linked to obesity disorder.